BOSTON, Feb. 27, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Raymond James 44th Annual Institutional Investors Conference on Monday, March 6, 2023, at 8:40 a.m. ET.
The public may access a live webcast of the fireside chat at Haemonetics' Investor Relations website or at: https://wsw.com/webcast/rj127/hae/1443508. A replay of the recorded webcast will become accessible 12 hours after the event and will be available for 90 days on Haemonetics' Investor Relations website.
Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.
Investor Contacts:
Olga Guyette, Sr. Director-Investor Relations & Treasury
(781) 356-9763
This email address is being protected from spambots. You need JavaScript enabled to view it.
David Trenk, Manager-Investor Relations
(203) 733-4987
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Josh Gitelson, Director-Global Communications
(781) 356-9776
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$74.83 |
Daily Change: | -0.25 -0.33 |
Daily Volume: | 721,740 |
Market Cap: | US$3.830B |
August 15, 2024 August 08, 2024 July 30, 2024 June 18, 2024 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB